Pulse Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

Pulse Biosciences

06/08/2026 23:41

Pulse Biosciences Inc PLSE.OQ reported a quarterly adjusted loss of 36 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -20 cents.  The mean expectation of three analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -45 cents to -31 cents per share.
Revenue was $434.00 thousand​; analysts expected $533.33 thousand. 
Pulse Biosciences Inc's reported EPS for the quarter was a loss of 36 cents​.
The company reported a quarterly loss of $24.66 million.
Pulse Biosciences Inc shares had risen by 36.7% this quarter and gained 176.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 14.3% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy" 
Wall Street's median 12-month price target for Pulse Biosciences Inc is $32.00, about 19.5% below its last closing price of $38.24
This summary was machine generated from LSEG data August 6 at 10:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.36
-0.36
Met
Mar. 31 2026 
-0.31
-0.24
Beat
Dec. 31 2025 
-0.31
-0.26
Beat
Sep. 30 2025 
-0.31
-0.29
Beat